Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(1)

Detailed Status

Active, not recruiting1

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

active_not_recruiting133%

completed133%

withdrawn133%

Recent Activity

1 active trials

Showing 3 of 3

active_not_recruitingphase_2

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

NCT05141721

withdrawnphase_2

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

NCT05456165

completedphase_1

A Study of a Personalized Neoantigen Cancer Vaccine

NCT03639714

Clinical Trials (3)

Showing 3 of 3 trials

NCT05141721Phase 2

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active Not Recruiting

NCT05456165Phase 2

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Withdrawn

NCT03639714Phase 1

A Study of a Personalized Neoantigen Cancer Vaccine

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3